If you have been reading about aminoisobutyric acid and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
=== Controlled Substances Act === Nixon announced his first major federal policy relating to the issue of substance abuse in 1970. Known as the Controlled Substances Act (CSA), it was ratified into law on September 7, 1970 and marked one of his administration's first major policy achievements. The CSA regulated at a federal level the manufacture, distribution, use, and distribution of certain substances. It placed all controlled substances into one of five scheduled classes based on their potential for abuse and ability to be used in medical treatment. One feature of the Act was the establishment of the National Commission on Marijuana and Drug Abuse, also known as the Shafer Commission, which was chaired by former Pennsylvania Governor Richard Shafer. Its purpose was to understand the extent of use of marijuana in the United States. The commission found that marijuana was undeserving to be classified as Schedule 1, the most dangerous classification, which included heroin and cocaine. In addition, the committee urged the administration to consider the potential of legalization laws in relation to marijuana. The drug historian, writer, and researcher Emily Dufton attests to Nixon's disdain for marijuana and his personal convictions of a connection between the drug and social rot. In addition, she argues that Nixon viewed marijuana as a "black drug" and that pursuing a punitive attitude towards the drug could offer significant political gain.
In 1889, under the Local Government Act 1888, the Cumberland County Council was created as the county council for Cumberland, taking over administrative functions from the Court of Quarter Sessions. The Local Government Act 1894 reconstituted the existing sanitary districts as urban districts and rural districts, each with an elected council. The Local Government Act 1888 also allowed any municipal borough with a population of 50,000 people or more to become a "county borough", independent of county council control. In 1914, Carlisle successfully applied for this status, ceasing to form part of the administrative county, although remaining within Cumberland for the purposes such as lieutenancy and shrievalty.
ATSDR Case Studies in Environmental Medicine: Beryllium Toxicity Archived 2016-02-04 at the Wayback Machine U.S. Department of Health and Human Services CDC – Research on Beryllium Sensitization and Chronic Beryllium Disease – NIOSH Workplace Safety and Health Topic Beryllium Network Archived 2009-02-28 at the Wayback Machine Health-cares.net Instant insight from the Royal Society of Chemistry examining the molecular basis of chronic beryllium disease Rosner, David; Markowitz, Gerald E. (February 1987). "Ch. 7: Salem Sarcoid:The Origins of Beryllium Disease". Dying for work: workers' safety and health in twentieth-century America. Indiana University Press. pp. 103–. ISBN 978-0-253-31825-1.
Cochran (born 1929), American chemist, known for pioneering studies on the nature of free radicals Ernst Cohen (1869–1944 Auschwitz), Dutch chemist known for work on the allotropy of metals) Mildred Cohn (1913–2009), American chemist, a pioneer in the applying nuclear magnetic resonance to enzyme reactions, particularly reactions of adenosine triphosphate David Collison (PhD 1980), British chemist known for development of electron paramagnetic resonance spectroscopy Vicki Colvin (born 1965), American chemist known for work on the synthesis and characterization of nanomaterials James Bryant Conant (1893–1978), American organic chemist who explored the complex relationship between chemical equilibrium and the reaction rate of chemical processes, Priestley Medal 1944 Elias James Corey (born 1928), American organic chemist, winner of the 1990 Nobel Prize in Chemistry for developing the theory and methodology of organic synthesis, specifically retrosynthetic analysis Robert Corey (1897–1971), American biochemist known for co-discovery of the α-helix and the β-sheet Carl Ferdinand Cori (1896–1984), Czech biochemist, Nobel Prize in physiology or medicine 1947 for discovering how glycogen is broken down and resynthesized Gerty Cori (1896–1957), American biochemist, Nobel Prize in physiology or medicine 1947 for discovering how glycogen is broken down and resynthesized John Cornforth (1917–2013), Australian-British chemist, 1975 Nobel Prize in Chemistry for work on the stereochemistry of enzyme-catalysed reactions Athel Cornish-Bowden (born 1943).
A ligament is a type of fibrous connective tissue in the body that connects bones to other bones. It also connects flight feathers to bones, in dinosaurs and birds. All 30,000 species of amniotes (land animals with internal bones) have ligaments. It is also known as articular ligament, articular larua, fibrous ligament, or true ligament.
Sources: en.wikipedia.org
CTCs can also be detected by using the acidification of the tumor microenvironment and the difference in membrane capacitance. CTCs are isolated from blood by a microfluidic device, and are cultured on-chip, which can be a method to capture more biological information in a single analysis. For example, it can be used to test the cell survival rate of 40 different drugs or drug combinations. Tumor‐derived extracellular vesicles can be isolated from urine and detected by an integrated double‐filtration microfluidic device; they also can be isolated from blood and detected by electrochemical sensing method with a two‐level amplification enzymatic assay. Tumor materials can directly be used for detection through microfluidic devices. To screen primary cells for drugs, it is often necessary to distinguish cancerous cells from non-cancerous cells. A microfluidic chip based on the capacity of cells to pass small constrictions can sort the cell types, metastases. Droplet‐based microfluidic devices have the potential to screen different drugs or combinations of drugs, directly on the primary tumor sample with high accuracy. To improve this strategy, the microfluidic program with a sequential manner of drug cocktails, coupled with fluorescent barcodes, is more efficient. Another advanced strategy is detecting growth rates of single-cell by using suspended microchannel resonators, which can predict drug sensitivities of rare CTCs. Microfluidics devices also can simulate the tumor microenvironment, to help to test anticancer drugs.
Income inequality decreased during Xi's tenure. Since 2021, Xi has promoted the term common prosperity, which he defined as an "essential requirement of socialism", described as affluence for all and said entailed reasonable adjustments to excess incomes. Common prosperity has been used as the justification for large-scale crackdowns and regulations towards the perceived "excesses" of several sectors, most prominently tech and tutoring industries. Actions taken include fining large tech companies and passing laws such as the Data Security Law. China introduced severe restrictions on private tutoring in the name of promoting social equality, effectively eliminating the private education industry. Xi opened a new stock exchange in Beijing targeted for small and medium enterprises (SMEs). There have been other cultural regulations including restrictions on minors playing video games and crackdowns on celebrity culture. The push for common prosperity has also included salary and bonus cuts, especially across the financial sector, as well as crackdowns on wealth flaunting.
== References == Nordin G, Dybkaer R. Recommendation for term and measurement unit for "HbA1c". Clin Chem Lab Med 2007; 45(8):1081-2. Summary of NPU definition publications René Dybkær: "An Ontology on Property for Physical, Chemical and Biological Systems" Berzell M., "Electronic Healthcare Ontologies: Philosophy, the real world and IT structures"
=== Development discontinued === AV-608 (CGP-60829; NK-608; NKP-608C; NKP608) – neurokinin NK1 receptor antagonist Cycloserine (D-cycloserine; TIK-101; TIK101) — NMDA receptor partial agonist Tradipitant (LY-686017; VLY-686) – neurokinin NK1 receptor antagonist Verucerfont (GSK-561679; NBI-77860) – corticotropin-releasing hormone receptor 1 (CRF1) antagonist
==== Complement Activation ==== The complement system includes blood proteins that can cause cell death after an antibody binds to the cell surface (the classical complement pathway, among the ways of complement activation). Generally, the system deals with foreign pathogens but can be activated with therapeutic antibodies in cancer. The system can be triggered if the antibody is chimeric, humanized, or human; as long as it contains the IgG1 Fc region. Complement can lead to cell death by activation of the membrane attack complex, known as complement-dependent cytotoxicity; enhancement of antibody-dependent cell-mediated cytotoxicity; and CR3-dependent cellular cytotoxicity. Complement-dependent cytotoxicity occurs when antibodies bind to the cancer cell surface, the C1 complex binds to these antibodies and subsequently, protein pores are formed in cancer cell membrane. Blocking Antibody therapies can also function by binding to proteins and physically blocking them from interacting with other proteins. Checkpoint inhibitors (CTLA-4, PD-1, and PD-L1) operate by this mechanism. Briefly, checkpoint inhibitors are proteins that normally help to slow immune responses and prevent the immune system from attacking normal cells. Checkpoint inhibitors bind these proteins and prevent them from functioning normally, which increases the activity of the immune system. Examples include durvalumab, ipilimumab, nivolumab, and pembrolizumab.
Sources: en.wikipedia.org
Warships, as an example, are designed to revel in controlled destruction; seeing a certain glory in achieving a 'worthwhile' death also seems characteristic. The presence of human crews on board warships may discourage such recklessness, since in the normal course of things, a Mind would not risk beings other than itself. With their almost godlike powers of reasoning and action comes a temptation to bend (or break) Cultural norms of ethical behaviour, if deemed necessary for some greater good. In The Player of Games, a Culture citizen is blackmailed, apparently by Special Circumstances Minds, into assisting the overthrow of a barbaric empire, while in Excession, a conspiracy by some Minds to start a war against an oppressive alien race nearly comes to fruition. Yet even in these rare cases, the essentially benevolent intentions of Minds towards other Culture citizens is never in question. More than any other beings in the Culture, Minds are the ones faced with the more complex and provocative ethical dilemmas.
== Specialty facilities == East Carolina Endoscopy Center East Carolina Heart Institute James & Connie Maynard Children's Hospital at ECU Health Medical Center Marion L. Shepard Cancer Center Onslow Radiation Oncology Service League of Greenville Inpatient Hospice ECU Health Behavioral Crisis Center ECU Health Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville ECU Health Cardiovascular & Pulmonary Rehabilitation ECU Health Health Foundation ECU Health Home Health & Hospice ECU Health Medical Group Practices ECU Health Minor Emergency ECU Health Outpatient Rehabilitation ECU Health Pain Management Centers ECU Health Radiation Oncology ECU Health Sleep Centers ECU Health SurgiCenter ECU Health Wellness Centers ECU Health Wound Healing Centers
Haemophilus is a genus of Gram-negative, pleomorphic, coccobacilli bacteria belonging to the family Pasteurellaceae. While Haemophilus bacteria are typically small coccobacilli, they are categorized as pleomorphic bacteria because of the wide range of shapes they occasionally assume. These organisms inhabit the mucous membranes of the upper respiratory tract, mouth, vagina, and intestinal tract. The genus includes commensal organisms along with some significant pathogenic species such as H. influenzae—a cause of sepsis and bacterial meningitis in young children—and H. ducreyi, the causative agent of chancroid. All members are either aerobic or facultatively anaerobic. This genus has been found to be part of the salivary microbiome.
=== Role of water === Water molecules play a significant role in the interactions between proteins. The crystal structures of complexes, obtained at high resolution from different but homologous proteins, have shown that some interface water molecules are conserved between homologous complexes. The majority of the interface water molecules make hydrogen bonds with both partners of each complex. Some interface amino acid residues or atomic groups of one protein partner engage in both direct and water mediated interactions with the other protein partner. Doubly indirect interactions, mediated by two water molecules, are more numerous in the homologous complexes of low affinity. Carefully conducted mutagenesis experiments, e.g. changing a tyrosine residue into a phenylalanine, have shown that water mediated interactions can contribute to the energy of interaction. Thus, water molecules may facilitate the interactions and cross-recognitions between proteins.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.